Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.98 |
| ▸ | RAD52 | P43351 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 7/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.56 |
| ▸ | HTR1D | P28221 | 4/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.56 |
| ▸ | HTR1B | P28222 | 3/20 | 0.56 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL564328 | 0.81 | CYP2D6 (0.68) | CYP2D6TSHRNFKB1HIF1AALDH1A1 | |
| Chloroethylclonidine SCHEMBL28305822 | 0.80 | CYP2D6 (0.65) | CYP2D6TSHRNFKB1HIF1AALDH1A1 | |
| Hydrochloric Acid SCHEMBL1322022 | 0.80 | LMNA (0.69) | CYP2D6TSHRNFKB1HIF1AALDH1A1 | |
| Hydrochloric Acid SCHEMBL7201422 | 0.80 | LMNA (0.69) | CYP2D6TSHRNFKB1HIF1AALDH1A1 | |
| SCHEMBL24658874 | 0.75 | ADRA2A (0.71) | CYP2D6TSHRNFKB1HIF1AALDH1A1 | |
| SCHEMBL11180812 | 0.75 | ADRA2A (0.76) | CYP2D6TSHRNFKB1HIF1AALDH1A1 | |
| SCHEMBL11761437 | 0.72 | ADRA2C (0.71) | CYP2D6TSHRNFKB1HIF1AALDH1A1 | |
| Pi-Clonidine SCHEMBL563884 | 0.72 | ADRA2A (1.00) | CYP2D6TSHRNFKB1HIF1AALDH1A1 | |
| SCHEMBL10414088 | 0.72 | ADRA2A (0.71) | CYP2D6TSHRNFKB1HIF1AALDH1A1 | |
| Apraclonidine SCHEMBL34128 | 0.72 | ADRA2A (1.00) | CYP2D6TSHRNFKB1HIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180098967-A1 | CLONIDINE AND/OR CLONIDINE DERIVATIVES FOR USE IN THE PREVENTION OF SKIN INJURY RESULTING FROM RADIOTHERAPY | Monopar Therapeutics Inc. | 2018-04-12 | — | — | US | claimed |
| EP-3294292-A1 | CLONIDINE AND/OR CLONIDINE DERIVATIVES FOR USE IN THE PREVENTION OF SKIN INJURY RESULTING FROM RADIOTHERAPY | Monopar Therapeutics Inc. (US) | 2018-03-21 | — | — | EP | claimed |
| WO-2016180834-A1 | CLONIDINE AND/OR CLONIDINE DERIVATIVES FOR USE IN THE PREVENTION OF SKIN INJURY RESULTING FROM RADIOTHERAPY | ONXEO (FR) | 2016-11-17 | — | — | WO | claimed |
| US-20210283217-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-16 | — | — | US | disclosed |
| US-20210177823-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-06-17 | — | — | US | disclosed |
| US-20210154272-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-05-27 | — | — | US | disclosed |
| US-20190240293-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE | CYGNAL THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| EP-3506926-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | Flagship Pioneering Innovations V, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-3490581-A2 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER | Flagship Pioneering Innovations V, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3294292-A1 | CLONIDINE AND/OR CLONIDINE DERIVATIVES FOR USE IN THE PREVENTION OF SKIN INJURY RESULTING FROM RADIOTHERAPY | Monopar Therapeutics Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-3283072-A1 | CLONIDINE AND/OR CLONIDINE DERIVATIVES FOR USE IN THE PREVENTION AND/OR TREATMENT OF ADVERSE SIDE EFFECTS OF CHEMOTHERAPY | Monopar Therapeutics Inc. (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2018022668-A2 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER | FLAGSHIP PIONEERING, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| WO-2018022664-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | FLAGSHIP PIONEERING, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| WO-2016180834-A1 | CLONIDINE AND/OR CLONIDINE DERIVATIVES FOR USE IN THE PREVENTION OF SKIN INJURY RESULTING FROM RADIOTHERAPY | ONXEO (FR) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016165775-A1 | CLONIDINE AND/OR CLONIDINE DERIVATIVES FOR USE IN THE PREVENTION AND/OR TREATMENT OF ADVERSE SIDE EFFECTS OF CHEMOTHERAPY | ONXEO (FR) | 2016-10-20 | — | — | WO | disclosed |
| CN-101878029-B | Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases | BONE THERAPEUTICS | 2013-04-03 | — | — | CN | disclosed |
| CN-101951903-A | Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases | BONE THERAPEUTICS | 2011-01-19 | — | — | CN | disclosed |
| CN-101878029-A | Be used for the treatment of and/or the pharmaceutical composition of prevention of osteoarticular diseases | BONE THERAPEUTICS | 2010-11-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180098967-A1 | CLONIDINE AND/OR CLONIDINE DERIVATIVES FOR USE IN THE PREVENTION OF SKIN INJURY RESULTING FROM RADIOTHERAPY | ADRA2C, ADRA2A, ADRA1A | CYP2D6 570/4885TSHR 3041/4885NFKB1 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.